GPT and metabolic dysfunction-associated steatohepatitis: In that biopsy-proven MASLD cohort, the aforementioned miRNA panel achieved an area under the receiver operating characteristic curve (AUROC) of about 0.81 for differentiating MASH from steatosis, essentially matching the AUROC of cytokeratin-18 (CK-18) M30 fragments—0.81—and outperforming ALT alone (AUROC~0.77) [30].